402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment.
Saved in:
| Title: | 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment. |
|---|---|
| Authors: | Lonardi, S.1 (AUTHOR), Pietrantonio, F.2 (AUTHOR), Prete, A.A.1 (AUTHOR), Messina, M.3 (AUTHOR), Formica, V.4 (AUTHOR), Corsi, D.C.5 (AUTHOR), Cortesi, E.6 (AUTHOR), Frassineti, L.G.7 (AUTHOR), Zampino, M.G.8 (AUTHOR), Ronzoni, M.9 (AUTHOR), Scartozzi, M.10 (AUTHOR), Casagrande, M.11 (AUTHOR), Conca, V.12 (AUTHOR), Bergamo, F.1 (AUTHOR), Prisciandaro, M.2 (AUTHOR), Intini, R.1 (AUTHOR), Antista, M.2 (AUTHOR), Paola, D.B.13 (AUTHOR), Vettore, V.1 (AUTHOR), Zagonel, V.1 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS412-S412. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
